Transforming clinical diagnostics: Advanced chemistry analyser with proven Six Sigma performance

Beckman Coulter Diagnostics, a leader in clinical diagnostics, will reveal its latest innovation, the DxC 500 AU Chemistry Analyzer, at Medlab Middle East in Dubai from 5-8 February 2024. This automated clinical chemistry analyser is part of Beckman Coulter's recent solutions aimed at addressing the diverse needs of healthcare systems. Specifically designed to enhance the capabilities of satellite and independent hospital laboratories, the DxC 500 AU complements central hub laboratories in adopting efficient hub-and-spoke models across global healthcare networks.

Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics, emphasised the strategic adoption of hub-and-spoke clinical laboratory models worldwide. These models optimise resources, improve access to testing services, and enhance standardisation, positively impacting inventory and cost management throughout health systems. The DxC 500 AU Chemistry Analyzer, with its extensive menu of high-quality assays, contributes to consistent and commutable results across Beckman Coulter's AU clinical chemistry systems, ultimately influencing clinical decision-making and patient outcomes.

The DxC 500 AU Chemistry Analyzer features advanced automation technology, guided workflows, and standardised reagents applicable across healthcare networks. Its menu, comprising over 120 assays, has undergone independent Six Sigma performance verification, instilling confidence in clinical results. This verification not only supports the assurance of quality in clinical outcomes but also reduces troubleshooting efforts and operational costs in laboratory management.

Sten Westgard, Director of Client Services and Technology for Westgard QC, affirmed that the DxC 500 AU Analyzer surpasses the demands of the new CLIA 2024 performance specifications based on their Six Sigma assessment. The analyser, designed for in vitro diagnostic use, is set for global commercial availability in March 2024.

More information online­